Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Leukosite (LKST)promising new biotech Cy? -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (28)	4/13/1999 10:22:00 AM
From: scaram(o)uche	Respond to of 35

alpha-v beta-3........ biz.yahoo.com

To: scaram(o)uche who wrote (28)	5/3/1999 2:08:00 PM
From: Luke	Read Replies (1) \| Respond to of 35

some interesting humanization patents that seem to be well regarded are 5,693,762 (Queen et al) 164.195.100.11 US 5,225,539 of Winter and 5,859,205 (celltech), among many others, i'm sure. Do you think that the major advantage of the Campath antibody is that one doesnt have to pay for this more recent technology, particularly the broader Queen patent (protein design labs)which lots of people seem to license? (off topic, so no answer needed if you dont feel like it: regarding Winter, there was a recent broad patent to antibodies resulting from phage display issued to Cambridge ab. technology last month. What do you think of CAT and their approach?